Pharma Market Access

Market Access in the Pharmaceutical Industry

Pharmaceutical market access teams exist to ensure effective medicines are available to the patients who need them. The patient access journey involves overcoming reimbursement and regulatory barriers to access, launching the product to market, and effectively communicating product value to healthcare decision makers.

To do this, Pharma market access teams must generate a comprehensive evidence base and demonstrate the clinical and economic value of their technology to reimbursement bodies, healthcare budget holders and, ultimately, prescribers.

How we support our Pharma clients

Our expert Pharma market access consultants and HEOR specialists support large, mid-size and smaller Pharmaceutical companies with each stage of the market access journey, from strategy to implementation.

With expertise across a wide range of disease areas and specialist teams in-house to support with all tactical needs, we are able to support our Pharma clients throughout their product lifecycle:

Click on the image to enlarge

To discuss your Pharma Market Access needs with our experts, get in touch using the form below.

    We are leaders in:

    Evidence

    Strategy, generation and planning

    Health economics

    • Health economic strategy
    • Early economic modelling
    • Global cost-effectiveness/HTA modelling
    • Budget impact models
    Read more

    Systematic review and meta-analysis

    • Evidence generation strategy
    • Systematic review
    • Network meta-analysis
    • Bespoke statistical analyses
    Read more

    Value and access

    Strategy and insight

    Global market access and pricing

    • Market access, value demonstration and pricing strategy
    • Landscape and opportunity assessment
    • Global Value Proposition development and testing
    • Global Value Dossiers and Objection Handlers
    Read more

    UK NHS insights

    • UK market access and NHS strategy
    • Delivery of honest and credible NHS insights
    • Facilitation of industry–NHS collaboration
    • Pathway mapping and stakeholder engagement
    Read more

    Communication

    Implementation and support

    HTA support

    • Cross-market HTA submissions
    • Reimbursement support dossiers
    • Scientific advice support
    Read more

    Customer communication

    • Digital value propositions
    • Localised BIMs
    • Interactive PDFs, E-detailers and IVAs
    • Flashcards, brochures, leave pieces
    • Healthcare insight dashboards
    Read more

    Why choose Mtech Access to support your Pharma market access strategy?

    • We have the in-house capability to support you through each stage of the product lifecycle or to supplement your teams’ capability where needed
    • We confirm the principles and assumptions behind our work with a broad network of payers, clinicians, and other stakeholders across global markets
    • In the UK we have close relationships with over 90+ contracted Associates working in the NHS, who work directly with us on projects to help us ensure our market access strategies and messages resonate with NHS decision-makers
    • We combine evidence and creativity, to deliver resources that work for your teams
    • We are a full-service Veeva partner, able to leverage Veeva’s full functionality to deliver the best possible experience for your teams and customers

    “Facing pressing resubmission deadlines, we reached out to Mtech Access to update our Systematic Literature Review and Data Analysis. I was very glad we did. We received the optimal outcome given the timelines – overall a very successful project!”

    Global HEOR DirectorPharma Company

    “It was great to get insights on the HTA landscape. The desk research done by Mtech Access was really detailed and identified a lot of gaps, whilst the experts that Mtech Access interviewed added a lot of value. The insights we gained have helped support our engagement with NICE and other stakeholders.”

    Health Economics ManagerTop 20 Pharma Company

    “The project was highly satisfying and exceeded all expectations. We were impressed by how comprehensive the research was, and how dedicated the team were.”

    Senior Market Access and Public Affairs ManagerTop 20 Pharma Company

    “The situation was challenging, and I don’t think we could have got through the [HTA submission] process without the quality of the work, the complete understanding of the process, and fantastic project management delivered by Mtech Access.”

    Head of Market Access, UK & IrelandPharma Company

    “I was really pleased with how the advisory board went. The outcomes were good and useful. If you are looking for something slightly different, go to Mtech.”

    Market Access ManagerTop 20 Pharma company

    “I just want to say that the payer research project was really great. I understood it was a challenge but the team did an amazing job.”

    HEOR Lead, Global Market Access Top 20 Pharma company

    Why choose Mtech Access to support your Pharma market access strategy?

    • We have the in-house capability to support you through each stage of the product lifecycle or to supplement your teams’ capability where needed
    • We confirm the principles and assumptions behind our work with a broad network of payers, clinicians, and other stakeholders across global markets
    • In the UK we have close relationships with over 80 contracted Associates working in the NHS, who work directly with us on projects to help us ensure our market access strategies and messages resonate with NHS decision-makers
    • We combine evidence and creativity, to deliver resources that work for your teams
    • We are a full-service Veeva partner, able to leverage Veeva’s full functionality to deliver the best possible experience for your teams and customers

    Articles related to Pharma Market Access

    How should Pharma approach market access in the 'New NHS'?

    How should Pharma approach market access in the ‘New NHS’?

    How will the legislation of Integrated Care Systems in July 2022, and the ‘New NHS’ impact on Pharma market access? NHS England is going through its most significant changes for…

    Mtech Access webinar: Rare disease market access: Strategic and tactical challenges facing orphan medicines entering Europe - with Rob Taaffe (Associate Consultant, Global Market Access) Regina Leadley (Consultant, Systematic Review) and Calum Jones (Consultant, Health Economist)

    Rare disease market access live webinar: Strategic and tactical challenges facing orphan medicines entering Europe

    In this webinar, we explored the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are…

    Changing spending priorities in pharmaceutical market access: pressures facing AIFA and other European agencies in a post-COVID era By Professor Fabrizio Gianfrate

    Changing spending priorities in pharmaceutical market access: pressures facing AIFA and other European agencies in a post-COVID era

    Guest author Professor Fabrizio Gianfrate shares his thoughts on how spending priorities have shifted in the pandemic, how they may further evolve in a post-COVID era, and how European agencies…